Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro

PURPOSE: Receptor tyrosine kinase inhibitors (RTKIs) are used as targeted therapies for patients diagnosed with cancer with highly expressed receptor tyrosine kinases (RTKs), including the platelet-derived growth factor receptor (PDGFR) and c-Kit receptor. Resistance to targeted therapies is partial...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourn, Jennifer, Cekanova, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005335/
https://www.ncbi.nlm.nih.gov/pubmed/29942116
http://dx.doi.org/10.2147/DDDT.S158518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005335/
https://www.ncbi.nlm.nih.gov/pubmed/29942116
http://dx.doi.org/10.2147/DDDT.S158518

Ejemplares similares